Why did GAAP EPS rise so much while Adjusted EPS grew only 4%?

GAAP EPS of $6.95 compared with $4.42 a year earlier, mainly because the prior-year quarter included a large provision for bad debts tied to the Rite Aid bankruptcy. Adjusted EPS excludes items like amortization, LIFO adjustments, and restructuring, and rose 4% to $8.03 on operating growth and a lower share count, partly offset by a higher tax rate.

Is the raised guidance a meaningful improvement?

Only modestly. The range was narrowed to $32.55 to $32.95 from $32.40 to $33.00, so the midpoint moved only slightly higher. Also, about $0.57 of the guidance comes from one-time-like investment gains at McKesson Ventures, so underlying core earnings growth is somewhat less than the headline suggests.

Why is free cash flow negative, and is it a concern?

Free cash flow was negative $2.2B for the nine months, as operating cash flow was negative $1.7B. Receivables grew $4.1B and inventories grew $3.1B, outpacing the $2.7B increase in payables, while capex and capitalized software totaled about $581M. Working capital timing can reverse, but investors should monitor whether cash conversion recovers by fiscal year-end, since shareholder returns were funded partly by new borrowings.

What does the PRISM Vision acquisition mean for McKesson?

McKesson agreed to acquire an 80% controlling interest in PRISM Vision Holdings, a provider of general ophthalmology and retina management services. Management frames it as a way to build a leading retinal care platform across providers, biopharma partners, and patients, using McKesson's oncology practice-management expertise. The deal is subject to customary closing conditions and regulatory clearance, and financial terms were not disclosed in this release.

Did this filing involve any new financial disclosures beyond the earnings release?

No. This is an amendment filed solely to add a dated conformed signature to the cover page. The substantive content is the furnished Exhibit 99.1 earnings release, which is not deemed filed under Section 18 of the Exchange Act. The release also includes the Rite Aid-related credit recorded in Q2 FY25 and the board additions made February 3, 2025.

MCK 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K/A filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.

This amended Form 8-K (filed to add a dated conformed signature to the original February 5, 2025 filing) furnishes McKesson's preliminary results for the fiscal 2025 third quarter ended December 31, 2024.

Revenue rose 18% to $95.3 billion^a, driven mainly by U.S. Pharmaceutical prescription volumes and oncology growth. GAAP diluted EPS was $6.95, up sharply from $4.42, but that comparison is flattered by the prior-year Rite Aid bad-debt charge. Adjusted EPS was $8.03, up 4%, helped by operating growth and a lower share count and held back by a higher tax rate.

Adjusted operating profit grew 16%. Management narrowed fiscal 2025 Adjusted EPS guidance to $32.55 to $32.95^b, from $32.40 to $33.00. The midpoint is essentially unchanged, and the range implies 19% to 20% growth.

Of that guidance, $0.57^c comes from year-to-date gains on McKesson Ventures equity investments, which investors should treat as lower-quality earnings. Cash generation was weak: operating cash flow was negative $1.7 billion and free cash flow was negative $2.2 billion for the nine months, largely due to working capital build in receivables and inventories. The company still returned $3.1 billion to shareholders through $2.8 billion of buybacks and $254 million of dividends.

Strategically, McKesson agreed to acquire an 80%^d controlling interest in PRISM Vision Holdings, a provider of ophthalmology and retina management services, subject to regulatory clearance. It also closed the sale of its Canadian Rexall and Well.ca retail businesses on December 30, 2024. Two new directors, Lynne Doughtie and Dr. Julie Gerberding, joined the board, bringing it to 13 members.

02—Key points

Key Highlights

Q3 FY25 revenue of $95.3B rose 18% year over year, led by U.S. Pharmaceutical (+19%) on higher prescription volumes and oncology growth.
GAAP diluted EPS of $6.95 (up 57%) was boosted by the lapping of a prior-year Rite Aid bad-debt charge; Adjusted EPS of $8.03 rose 4%.
Fiscal 2025 Adjusted EPS guidance narrowed to $32.55 to $32.95 (low end raised, high end lowered), implying 19% to 20% growth; $0.57 of this comes from year-to-date McKesson Ventures investment gains.
Nine-month free cash flow was negative $2.2B, driven by operating cash outflow of $1.7B and higher receivables and inventories, despite $3.1B returned to shareholders.
Agreed to acquire an 80% controlling interest in PRISM Vision Holdings (retina and ophthalmology services), subject to regulatory clearance, extending the oncology-style platform model into specialty care.
Closed the divestiture of Canadian Rexall and Well.ca retail businesses on December 30, 2024; International Adjusted Operating Profit rose 18% partly due to ceasing D&A on those assets.
Balance sheet shows total deficit of $2.7B and short-term borrowings of $2.4B, with cash down to $1.1B from $4.6B at March 2024.

03—Questions

Frequently Asked Questions

Why did GAAP EPS rise so much while Adjusted EPS grew only 4%?
GAAP EPS of $6.95 compared with $4.42 a year earlier, mainly because the prior-year quarter included a large provision for bad debts tied to the Rite Aid bankruptcy. Adjusted EPS excludes items like amortization, LIFO adjustments, and restructuring, and rose 4% to $8.03 on operating growth and a lower share count, partly offset by a higher tax rate.
Is the raised guidance a meaningful improvement?
Only modestly. The range was narrowed to $32.55 to $32.95 from $32.40 to $33.00, so the midpoint moved only slightly higher. Also, about $0.57 of the guidance comes from one-time-like investment gains at McKesson Ventures, so underlying core earnings growth is somewhat less than the headline suggests.
Why is free cash flow negative, and is it a concern?
Free cash flow was negative $2.2B for the nine months, as operating cash flow was negative $1.7B. Receivables grew $4.1B and inventories grew $3.1B, outpacing the $2.7B increase in payables, while capex and capitalized software totaled about $581M. Working capital timing can reverse, but investors should monitor whether cash conversion recovers by fiscal year-end, since shareholder returns were funded partly by new borrowings.
What does the PRISM Vision acquisition mean for McKesson?
McKesson agreed to acquire an 80% controlling interest in PRISM Vision Holdings, a provider of general ophthalmology and retina management services. Management frames it as a way to build a leading retinal care platform across providers, biopharma partners, and patients, using McKesson's oncology practice-management expertise. The deal is subject to customary closing conditions and regulatory clearance, and financial terms were not disclosed in this release.
Did this filing involve any new financial disclosures beyond the earnings release?
No. This is an amendment filed solely to add a dated conformed signature to the cover page. The substantive content is the furnished Exhibit 99.1 earnings release, which is not deemed filed under Section 18 of the Exchange Act. The release also includes the Rite Aid-related credit recorded in Q2 FY25 and the board additions made February 3, 2025.

04—Continue

← View all 8-K filings